MS
DSGN icon

Maven Securities’s Design Therapeutics DSGN Stock Holding History

Maven Securities’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,000
Closed -$299K – 1126
2021
Q1 		$299K Buy
+10,000
New +$337K 0.01% 807

Other funds holding DSGN

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maven Securities's DSGN Position: Q2 2021 in Review

Maven Securities sold out of Design Therapeutics (DSGN) in Q2 2021, closing a stake of 10,000 shares — an estimated $299K sold.

Maven Securities first reported a position in DSGN in Q1 2021 and held it in 1 quarter. The position peaked at $299K in Q1 2021. 50 funds tracked by Wall St. Rank hold DSGN as of Q2 2021.

  • Maven Securities reported no remaining Design Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 10,000 Design Therapeutics shares in Q2 2021, an estimated $299K.
  • Maven Securities first reported a position in Design Therapeutics in Q1 2021 and held it in 1 quarter.
  • Maven Securities's Design Therapeutics position peaked at $299K in Q1 2021.
  • 50 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.